Is ENGN or DARE more profitable?

Dare Bioscience's return on equity of 0.00% beat enGene's return on equity. Company Net Margins Return on Equity Return on Assets enGene N/A -55.83% -45.74% Dare Bioscience N/A N/A -46.22%

Is DARE or BDTX more profitable?

Dare Bioscience's return on equity of 0.00% beat Black Diamond Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Dare Bioscience N/A N/A -46.22% Black Diamond Therapeutics N/A -30.18% -23.91%

Do analysts rate LIXT or DARE?

Dare Bioscience has a consensus price target of $10.00, indicating a potential upside of 395.05%. Given Dare Bioscience's stronger consensus rating and higher probable upside, analysts clearly believe Dare Bioscience is more favorable than Lixte Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lixte Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Dare Bioscience 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Is LIXT or DARE more profitable?

Dare Bioscience's return on equity of 0.00% beat Lixte Biotechnology's return on equity. Company Net Margins Return on Equity Return on Assets Lixte Biotechnology N/A -134.91% -95.61% Dare Bioscience N/A N/A -46.22%

Is PYXS or DARE more profitable?

Dare Bioscience's return on equity of 0.00% beat Pyxis Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Pyxis Oncology N/A -135.60% -85.00% Dare Bioscience N/A N/A -46.22%

Which has better earnings & valuation, DARE or PLYX?

Polaryx Therapeutics has lower revenue, but higher earnings than Dare Bioscience. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Dare Bioscience $1.03M 29.38 -$13.40M -$0.95 N/A Polaryx Therapeutics N/A N/A N/A N/A N/A

Is DARE or PLYX more profitable?

Company Net Margins Return on Equity Return on Assets Dare Bioscience N/A N/A -46.22% Polaryx Therapeutics N/A N/A N/A

Dare Bioscience (DARE) Competitors

$2.02 0.00 (0.00%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$2.03 +0.01 (+0.69%)

As of 06/12/2026 07:59 PM Eastern

Compare

DARE vs. ENGN, BDTX, LIXT, PYXS, and PLYX

Should you buy Dare Bioscience stock or one of its competitors? MarketBeat compares Dare Bioscience with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Dare Bioscience include enGene (ENGN), Black Diamond Therapeutics (BDTX), Lixte Biotechnology (LIXT), Pyxis Oncology (PYXS), and Polaryx Therapeutics (PLYX). These companies are all part of the "pharmaceutical products" industry.

How does Dare Bioscience compare to enGene?

enGene (NASDAQ:ENGN) and Dare Bioscience (NASDAQ:DARE) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, valuation, profitability, analyst recommendations, earnings and dividends.

In the previous week, enGene had 10 more articles in the media than Dare Bioscience. MarketBeat recorded 11 mentions for enGene and 1 mentions for Dare Bioscience. Dare Bioscience's average media sentiment score of 1.89 beat enGene's score of 0.08 indicating that Dare Bioscience is being referred to more favorably in the news media.

Company	Overall Sentiment
enGene	Neutral
Dare Bioscience	Very Positive

enGene presently has a consensus price target of $12.68, suggesting a potential upside of 682.83%. Dare Bioscience has a consensus price target of $10.00, suggesting a potential upside of 395.05%. Given enGene's higher possible upside, equities analysts plainly believe enGene is more favorable than Dare Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
enGene	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21
Dare Bioscience	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Dare Bioscience has higher revenue and earnings than enGene. Dare Bioscience is trading at a lower price-to-earnings ratio than enGene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
enGene	N/A	N/A	-$117.30M	-$2.25	N/A
Dare Bioscience	$1.03M	29.38	-$13.40M	-$0.95	N/A

enGene has a beta of -0.29, suggesting that its share price is 129% less volatile than the broader market. Comparatively, Dare Bioscience has a beta of 1.07, suggesting that its share price is 7% more volatile than the broader market.

64.2% of enGene shares are owned by institutional investors. Comparatively, 6.7% of Dare Bioscience shares are owned by institutional investors. 10.5% of enGene shares are owned by company insiders. Comparatively, 4.1% of Dare Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Dare Bioscience's return on equity of 0.00% beat enGene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
enGene	N/A	-55.83%	-45.74%
Dare Bioscience	N/A	N/A	-46.22%

Summary

enGene and Dare Bioscience tied by winning 7 of the 14 factors compared between the two stocks.

How does Dare Bioscience compare to Black Diamond Therapeutics?

Dare Bioscience (NASDAQ:DARE) and Black Diamond Therapeutics (NASDAQ:BDTX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, dividends, risk, earnings, media sentiment and valuation.

Dare Bioscience's return on equity of 0.00% beat Black Diamond Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dare Bioscience	N/A	N/A	-46.22%
Black Diamond Therapeutics	N/A	-30.18%	-23.91%

In the previous week, Dare Bioscience and Dare Bioscience both had 1 articles in the media. Black Diamond Therapeutics' average media sentiment score of 1.90 beat Dare Bioscience's score of 1.89 indicating that Black Diamond Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Dare Bioscience	Very Positive
Black Diamond Therapeutics	Very Positive

Black Diamond Therapeutics has higher revenue and earnings than Dare Bioscience. Black Diamond Therapeutics is trading at a lower price-to-earnings ratio than Dare Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dare Bioscience	$1.03M	29.38	-$13.40M	-$0.95	N/A
Black Diamond Therapeutics	$70M	1.43	$22.37M	-$0.77	N/A

6.7% of Dare Bioscience shares are held by institutional investors. Comparatively, 95.5% of Black Diamond Therapeutics shares are held by institutional investors. 4.1% of Dare Bioscience shares are held by company insiders. Comparatively, 9.3% of Black Diamond Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Dare Bioscience has a beta of 1.07, meaning that its stock price is 7% more volatile than the broader market. Comparatively, Black Diamond Therapeutics has a beta of 3.22, meaning that its stock price is 222% more volatile than the broader market.

Dare Bioscience presently has a consensus target price of $10.00, indicating a potential upside of 395.05%. Black Diamond Therapeutics has a consensus target price of $10.00, indicating a potential upside of 471.43%. Given Black Diamond Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Black Diamond Therapeutics is more favorable than Dare Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dare Bioscience	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Black Diamond Therapeutics	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.73

Summary

Black Diamond Therapeutics beats Dare Bioscience on 12 of the 15 factors compared between the two stocks.

How does Dare Bioscience compare to Lixte Biotechnology?

Lixte Biotechnology (NASDAQ:LIXT) and Dare Bioscience (NASDAQ:DARE) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, analyst recommendations, valuation, dividends, risk, profitability and media sentiment.

Lixte Biotechnology has a beta of 1.27, meaning that its stock price is 27% more volatile than the broader market. Comparatively, Dare Bioscience has a beta of 1.07, meaning that its stock price is 7% more volatile than the broader market.

Dare Bioscience's return on equity of 0.00% beat Lixte Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lixte Biotechnology	N/A	-134.91%	-95.61%
Dare Bioscience	N/A	N/A	-46.22%

In the previous week, Lixte Biotechnology had 5 more articles in the media than Dare Bioscience. MarketBeat recorded 6 mentions for Lixte Biotechnology and 1 mentions for Dare Bioscience. Dare Bioscience's average media sentiment score of 1.89 beat Lixte Biotechnology's score of 0.02 indicating that Dare Bioscience is being referred to more favorably in the news media.

Company	Overall Sentiment
Lixte Biotechnology	Neutral
Dare Bioscience	Very Positive

Lixte Biotechnology has higher earnings, but lower revenue than Dare Bioscience. Lixte Biotechnology is trading at a lower price-to-earnings ratio than Dare Bioscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lixte Biotechnology	N/A	N/A	-$6.01M	-$1.13	N/A
Dare Bioscience	$1.03M	29.38	-$13.40M	-$0.95	N/A

Dare Bioscience has a consensus price target of $10.00, indicating a potential upside of 395.05%. Given Dare Bioscience's stronger consensus rating and higher probable upside, analysts clearly believe Dare Bioscience is more favorable than Lixte Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lixte Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Dare Bioscience	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

5.1% of Lixte Biotechnology shares are owned by institutional investors. Comparatively, 6.7% of Dare Bioscience shares are owned by institutional investors. 9.5% of Lixte Biotechnology shares are owned by company insiders. Comparatively, 4.1% of Dare Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Dare Bioscience beats Lixte Biotechnology on 10 of the 14 factors compared between the two stocks.

How does Dare Bioscience compare to Pyxis Oncology?

Pyxis Oncology (NASDAQ:PYXS) and Dare Bioscience (NASDAQ:DARE) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, risk, institutional ownership, valuation, analyst recommendations, dividends and media sentiment.

39.1% of Pyxis Oncology shares are held by institutional investors. Comparatively, 6.7% of Dare Bioscience shares are held by institutional investors. 10.6% of Pyxis Oncology shares are held by company insiders. Comparatively, 4.1% of Dare Bioscience shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Pyxis Oncology presently has a consensus target price of $6.83, suggesting a potential upside of 288.26%. Dare Bioscience has a consensus target price of $10.00, suggesting a potential upside of 395.05%. Given Dare Bioscience's higher probable upside, analysts clearly believe Dare Bioscience is more favorable than Pyxis Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pyxis Oncology	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Dare Bioscience	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Dare Bioscience's return on equity of 0.00% beat Pyxis Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pyxis Oncology	N/A	-135.60%	-85.00%
Dare Bioscience	N/A	N/A	-46.22%

In the previous week, Pyxis Oncology had 1 more articles in the media than Dare Bioscience. MarketBeat recorded 2 mentions for Pyxis Oncology and 1 mentions for Dare Bioscience. Dare Bioscience's average media sentiment score of 1.89 beat Pyxis Oncology's score of 1.68 indicating that Dare Bioscience is being referred to more favorably in the news media.

Company	Overall Sentiment
Pyxis Oncology	Very Positive
Dare Bioscience	Very Positive

Pyxis Oncology has a beta of 1.42, meaning that its share price is 42% more volatile than the broader market. Comparatively, Dare Bioscience has a beta of 1.07, meaning that its share price is 7% more volatile than the broader market.

Dare Bioscience has lower revenue, but higher earnings than Pyxis Oncology. Dare Bioscience is trading at a lower price-to-earnings ratio than Pyxis Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pyxis Oncology	$13.86M	8.05	-$79.62M	-$1.31	N/A
Dare Bioscience	$1.03M	29.38	-$13.40M	-$0.95	N/A

Summary

Pyxis Oncology beats Dare Bioscience on 8 of the 15 factors compared between the two stocks.

How does Dare Bioscience compare to Polaryx Therapeutics?

Dare Bioscience (NASDAQ:DARE) and Polaryx Therapeutics (NASDAQ:PLYX) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings, media sentiment and analyst recommendations.

In the previous week, Polaryx Therapeutics had 1 more articles in the media than Dare Bioscience. MarketBeat recorded 2 mentions for Polaryx Therapeutics and 1 mentions for Dare Bioscience. Dare Bioscience's average media sentiment score of 1.89 beat Polaryx Therapeutics' score of 0.44 indicating that Dare Bioscience is being referred to more favorably in the media.

Company	Overall Sentiment
Dare Bioscience	Very Positive
Polaryx Therapeutics	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Dare Bioscience	N/A	N/A	-46.22%
Polaryx Therapeutics	N/A	N/A	N/A

6.7% of Dare Bioscience shares are owned by institutional investors. 4.1% of Dare Bioscience shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Polaryx Therapeutics has lower revenue, but higher earnings than Dare Bioscience.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dare Bioscience	$1.03M	29.38	-$13.40M	-$0.95	N/A
Polaryx Therapeutics	N/A	N/A	N/A	N/A	N/A

Dare Bioscience presently has a consensus price target of $10.00, indicating a potential upside of 395.05%. Polaryx Therapeutics has a consensus price target of $10.00, indicating a potential upside of 321.94%. Given Dare Bioscience's stronger consensus rating and higher possible upside, analysts plainly believe Dare Bioscience is more favorable than Polaryx Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dare Bioscience	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Polaryx Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Dare Bioscience beats Polaryx Therapeutics on 7 of the 9 factors compared between the two stocks.

Get Dare Bioscience News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DARE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DARE vs. The Competition

Export

Metric	Dare Bioscience	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$30.26M	$3.39B	$6.52B	$12.05B
Dividend Yield	N/A	2.25%	2.67%	5.66%
P/E Ratio	-2.13	20.00	24.00	24.42
Price / Sales	29.38	303.75	533.77	123.88
Price / Cash	N/A	53.61	27.48	37.92
Price / Book	10.10	8.32	10.55	6.82
Net Income	-$13.40M	$23.94M	$3.57B	$337.56M
7 Day Performance	9.19%	1.84%	0.59%	1.16%
1 Month Performance	-6.91%	-0.04%	1.55%	3.16%
1 Year Performance	-33.33%	44.82%	25.41%	30.60%

Dare Bioscience Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DARE Dare Bioscience	2.4034 of 5 stars	$2.02 flat	$10.00 +395.0%	-33.3%	$30.26M	$1.03M	N/A	30	Positive News
ENGN enGene	3.7226 of 5 stars	$1.67 +0.9%	$12.68 +661.7%	-51.4%	$111.54M	N/A	N/A	31
BDTX Black Diamond Therapeutics	3.6152 of 5 stars	$1.93 +4.1%	$10.00 +419.5%	-24.2%	$109.73M	$70M	N/A	90	Positive News Gap Up
LIXT Lixte Biotechnology	0.2662 of 5 stars	$7.28 +9.5%	N/A	+443.0%	$108.60M	N/A	N/A	4	Analyst Upgrade Gap Up High Trading Volume
PYXS Pyxis Oncology	3.6502 of 5 stars	$1.72 +1.5%	$6.83 +298.4%	+46.7%	$108.02M	$13.86M	N/A	60	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DARE) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Dare Bioscience (DARE) Competitors

DARE vs. ENGN, BDTX, LIXT, PYXS, and PLYX

How does Dare Bioscience compare to enGene?

Summary

How does Dare Bioscience compare to Black Diamond Therapeutics?

Summary

How does Dare Bioscience compare to Lixte Biotechnology?

Summary

How does Dare Bioscience compare to Pyxis Oncology?

Summary

How does Dare Bioscience compare to Polaryx Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DARE vs. The Competition

Dare Bioscience Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Dare Bioscience (DARE) Competitors

DARE vs. ENGN, BDTX, LIXT, PYXS, and PLYX

How does Dare Bioscience compare to enGene?

Does the media refer more to ENGN or DARE?

Do analysts prefer ENGN or DARE?

Which has stronger earnings & valuation, ENGN or DARE?

Which has more volatility & risk, ENGN or DARE?

Do insiders & institutionals have more ownership in ENGN or DARE?

Is ENGN or DARE more profitable?

Summary

How does Dare Bioscience compare to Black Diamond Therapeutics?

Is DARE or BDTX more profitable?

Does the media favor DARE or BDTX?

Which has preferable valuation & earnings, DARE or BDTX?

Do insiders and institutionals believe in DARE or BDTX?

Which has more volatility and risk, DARE or BDTX?

Do analysts prefer DARE or BDTX?

Summary

How does Dare Bioscience compare to Lixte Biotechnology?

Which has more risk and volatility, LIXT or DARE?

Is LIXT or DARE more profitable?

Does the media refer more to LIXT or DARE?

Which has better earnings & valuation, LIXT or DARE?

Do analysts rate LIXT or DARE?

Do institutionals & insiders have more ownership in LIXT or DARE?

Summary

How does Dare Bioscience compare to Pyxis Oncology?

Do institutionals and insiders hold more shares of PYXS or DARE?

Do analysts recommend PYXS or DARE?

Is PYXS or DARE more profitable?

Does the media refer more to PYXS or DARE?

Which has more risk & volatility, PYXS or DARE?

Which has preferable earnings & valuation, PYXS or DARE?

Summary

How does Dare Bioscience compare to Polaryx Therapeutics?

Does the media prefer DARE or PLYX?

Is DARE or PLYX more profitable?

Do institutionals & insiders believe in DARE or PLYX?

Which has better earnings & valuation, DARE or PLYX?

Do analysts prefer DARE or PLYX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DARE vs. The Competition

Dare Bioscience Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools